Voyager Therapeutics Announces Additional Data at the American Society of Gene and Cell Therapy 2018 Annual Meeting Voyager’s gene therapy vector for Friedreich’s ataxia prevents central and peripheral disease progression in preclinical model out to one year after a single administration Durable safety data...